How to Operationalize Decentralized Clinical Trials for GxP Compliance

The clinical trial model that carried drug development through the 20th century can no longer meet the demands of modern drug development. Enrollment takes too long, trial populations look nothing like real patients, and the infrastructure required to run a traditional, site-centric study has become a barrier to innovation, not an enabler of it.

Decentralized Clinical Trials (DCTs) and Real-World Evidence (RWE) have emerged as the industry's answer. They offer genuine promise: faster recruitment, broader demographic reach, and a richer, more continuous data stream that was impossible to capture inside a clinic.

However, the very flexibility that defines a DCT becomes its greatest liability without a robust governance infrastructure. When you decentralize the site, you must centralize the control. Remote data collection introduces multiple data sources, multiple systems, multiple jurisdictions, and multiple potential points of failure. Before the industry can unlock the full promise of decentralized research, it must solve the data problem.

This piece explores what it actually takes to operationalize a DCT, maintain GxP compliance in a remote environment, and turn real-world evidence into a regulatory asset rather than a liability.

Late-stage development timelines frequently stretch across six or more years, with Phase III execution alone typically spanning multiple years. Trial participants have historically skewed toward white populations and patients living near academic medical centers, with persistent underrepresentation across race, age, and geography.

These have been industry realities for decades. What has changed is the regulatory and competitive pressure to address them. The FDA's Real-World Evidence Program, the updated ICH E6(R3) Guideline, and the EU Clinical Trials Regulation all signal the same direction: the future of drug development is decentralized, patient-centric, and data-driven.

Decentralized trials don't just change where research happens. They change what is possible to measure, who can participate, and how quickly an organization can generate evidence. But that expanded capability comes with an expanded responsibility for data governance.

GxP compliance in a decentralized clinical trial environment refers to meeting the full set of Good Clinical Practice, with integration of applicable Good Laboratory Practice and Good Manufacturing Practice controls across a distributed, remote infrastructure — rather than within a single, controlled site setting.

One of the most common and costly misconceptions in DCT planning is the assumption that GxP obligations are primarily a site responsibility. They are not. Organizations remain accountable for the quality, integrity, and traceability of all trial data, regardless of where or how it is collected.

ICH E6(R3), finalized in 2025, makes this explicit. The revised guideline moves away from prescriptive, site-based monitoring toward a risk-based, proportionate oversight model that places the burden directly on the organization to identify, assess, and mitigate data risks across the entire trial ecosystem — including every remote touchpoint.

For a decentralized trial, that means your GxP compliance program must extend to:

Risk-based monitoring (RBM) in a decentralized clinical trial is a systematic, data-driven approach to directing oversight resources to the areas of greatest risk to patient safety and data integrity — replacing the traditional model of periodic, comprehensive on-site monitoring visits with continuous, centralized signal detection across all remote data streams.

RBM has been part of the regulatory conversation since the FDA's 2013 guidance and EMA's subsequent reflection paper. But many organizations still operate it as fewer on-site visits rather than what it actually is: a proactive intelligence system built on real-time data.

In a DCT context, the absence of a physical site means you lose the informal oversight that happens naturally during a monitoring visit. You must replace that informal oversight with structured, signal-based monitoring built on centralized data review.

A well-designed RBM program for a decentralized trial includes:

The FDA has supported dozens of regulatory decisions and labeling expansions where real-world evidence played a contributory role. The opportunity is real and growing. But for every successful RWE submission, there are many more that fail — not because the data was wrong, but because the methodology was not defensible.

Real-world data derived from electronic health records, claims databases, or patient registries can be extraordinarily powerful. It can support label extensions, inform synthetic control arms, and accelerate post-market commitments. But RWE is only as valuable as its provenance.

Regulators scrutinize the source, the completeness, the methodology, and the potential for bias with the same rigor they apply to primary efficacy data. What separates successful RWE submissions from failed ones is governance:

Decentralized clinical trials and real-world evidence represent a genuine inflection point for drug development. The regulatory frameworks are maturing. The technology is proven. Patient demand for more accessible trial participation is real and growing.

What the industry has not yet fully solved is the operational layer — the governance, monitoring, compliance, and data management infrastructure that transforms an innovative trial design into an audit-ready, submission-quality evidence package.

That is precisely where the difference between a DCT that accelerates a program and one that creates a regulatory problem is made. It's made in the data management plan, the vendor oversight program, the risk-based monitoring architecture, and the RWE methodology — not in the technology platform or the protocol design.

The organizations that will lead the next decade of drug development are those who build the operational infrastructure to match their scientific ambition. Decentralization is a strategy. Data integrity is non-negotiable.